ClinicalTrials.gg
Active, not recruitingNCT03725007SELECT-YOUTHUpdated Aug 3, 2026

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

A Phase 1 interventional study of Upadacitinib in Juvenile Idiopathic Arthritis (JIA), sponsored by AbbVie. Active, not recruiting at 35 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Arthritis, Juvenile by AbbVie — 2 open to participants now, 3 under way, 2 of them phase 3. Arthritis, Juvenile · AbbVie.

Started
2019
the only one that year
Phase 1
Only one
of the 10
Registered
7th of 10
by date

Among the 10 studies in Arthritis, Juvenile by AbbVie, this one is the only one that started in 2019, is the only one in phase 1, and was the 7th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 10 studies in Arthritis, Juvenile by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by AbbVie, or all of them as a file.
02

Study summary

This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of three parts: Part 1 is multiple-cohort study that consists of two sequential multiple dose groups. Participants benefiting from the study drug with no ongoing adverse events of special interest or serious adverse events will have option to enroll in Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability. Part 3 is an additional safety cohort to evaluate long-term safety and tolerability. Participants \<18 years of age who are ongoing in Parts 2 and 3 will participate in an 104 week open-label extension of the study in Part 4.

03

Conditions studied

  • Juvenile Idiopathic Arthritis (JIA)

Browse trials for

Keywords

  • Upadacitinib
  • ABT-494
  • Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA)
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant have total body weight of 10 kg or higher at the time of screening.
  • Participant diagnosed with pcJIA (rheumatoid factor-positive or rheumatoid factor-negative polyarticular JIA, extended oligoarticular JIA, or systemic JIA with active arthritis and without active systemic features) with a history of arthritis affecting at least 5 joints within the first 6 months of disease (for extended oligoarticular JIA: \<=4 joints within first 6 months of disease and >4 joints thereafter).
  • Participant have 5 or more active joints at the time of screening, defined as the presence of swollen joints (not due to deformity) or, in the absence of swelling, joints with the limitation of movement (LOM) plus pain on motion and/or tenderness with palpitation, with LOM present in at least three of the active joints.
  • If receiving methotrexate (MTX), have been taking MTX for at least 12 weeks immediately before and including Study Day 1 on a stable dose of \<=20 mg/m2 for at least 8 weeks before and including Study Day 1; in addition, participants should take either folic acid or folinic acid according to local standard of care.
  • If on oral glucocorticosteroids, must have been taking oral glucocorticosteroids at a stable dose (no greater than 10 mg/day or 0.2 mg/kg/day, whatever is lower) for at least 1 week before and including Study Day 1.

Exclusion criteria

Exclusion Criteria:

  • Participant with diagnosis of enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (JPSA).
  • Participant have prior exposure to JAK inhibitor.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Participants of age group 12 to <18 years receiving dose A

    Participants of age group 12 to \<18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Drug: Upadacitinib

  • Experimental
    Participants of age group 12 to <18 years receiving dose B

    Participants of age group 12 to \<18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.

    Drug: Upadacitinib

  • Experimental
    Participants of age group 6 to <12 years receiving dose A

    Participants of age group 6 to \<12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Drug: Upadacitinib

  • Experimental
    Participants of age group 2 to <6 years receiving dose A

    Participants of age group 2 to \<6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Drug: Upadacitinib

  • Experimental
    Participants of age group 2 to <18 years receiving dose A

    Participants of age group 2 to \<18 years administered with upadacitinib dose A as described in the protocol.

    Drug: Upadacitinib

Interventions

  • Upadacitinib is administered as an oral solution or tablet as described in protocol.

    Also known as: ABT-494

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (TEAEs)

    Adverse Event is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product.

    Time frame: Up to approximately 260 weeks

  2. Part 1: Maximum observed plasma concentration (Cmax)

    Cmax is defined as the maximum observed plasma concentration for upadacitinib.

    Time frame: Day 7

  3. Part 1: Time to maximum observed plasma concentration (Tmax)

    Tmax is defined as the time to maximum plasma concentration (Cmax) of upadacitinib.

    Time frame: Day 7

  4. Part 1: Area under plasma concentration versus time curve during a dosing interval (AUCtau)

    The area under the plasma concentration-time curve is a method of measurement of the total exposure of a drug in plasma.

    Time frame: Day 7

  5. Part 1: Apparent oral clearance at steady state (CL/F)

    Clearance is defined as the volume of plasma cleared of the drug per unit time.

    Time frame: Day 7

  6. Part 1: Half-life

    Half life of updadacitinib will be determined using non-compartmental method.

    Time frame: Day 7

07

Study locations

35 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2019 (actual). Primary completion is estimated for Dec 2028, 114 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2018
First posted
Oct 30, 2018
StartActual
Jun 24, 2019
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03725007
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 30, 2018
Start date
Jun 24, 2019
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Aug 3, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion